Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Maior pesquisa epidemiológica da história sobre doença venosa crônica, incluindo 70.000 pacientes mostra a importância do tratamento precoce
  • Latin America - español

- "Diagnóstico precoce e tratamento da doença venosa crônica são obrigatórios para prevenir progressão a estágios clínicos mais graves inclusive de úlceras venosas"


News provided by

Servier

Sep 14, 2011, 03:00 ET

Share this article

Share toX

Share this article

Share toX

PRAGA, 14 de setembro de 2011 /PRNewswire/ -- O Programa VEIN CONSULT, a maior pesquisa epidemiológica da história sobre doença venosa crônica realizada sob os auspícios da União Internacional de Flebologia (UIP) e apoiada por uma subvenção irrestrita do Servier Research Group, é um esforço internacional de educação para aumentar a conscientização da DCV entre pacientes, cientistas e autoridades de saúde. É a primeira pesquisa a avaliar um número tão grande de pacientes de vários países de diversas áreas geográficas (Europa, Oriente Médio, Extremo Oriente, América Central e América Latina), utilizando o mesmo questionário e a mesma classificação (classificação CEAP).

Os primeiros resultados do Programa VEIN CONSULT mostram que essa doença venosa crônica tem um impacto negativo significativo nas vidas profissionais dos pacientes, resultando em perdas grandes de produtividade; 15% dos pacientes com doença venosa crônica relatam a perda de dias de trabalho. A DVC também é responsável pelo sofrimento físico e psicológico dos pacientes que se refletem na piora da qualidade de vida. Observamos uma deterioração significativa na qualidade de vida com o aumento da gravidade da doença. Isto afeta diretamente os custos relacionados à DVC, cerca de 4% dos pacientes tiveram de mudar de emprego por causa de sua doença venosa e mais de 6% tiveram que ser hospitalizados.

Pela primeira vez, os pacientes sintomáticos são avaliados e a DVC é detectada desde as fases iniciais, com o objetivo de melhorar o processo de tratamento.

Oito em cada 10 pacientes sofrem de doença venosa crônica da primeira dor venosa a estágios mais avançados, tais como edema e úlcera. Graças ao Programa VEIN CONSULT, podemos avaliar pela primeira vez, a prevalência de pacientes com DVC com apenas sintomas (dor nas pernas, sensação de peso, inchaço...). Isso mostra que 20% dos primeiros participantes de vários países são classificados como pacientes com sintomas apenas, enquanto 61,2% são classificados como pacientes com sinais visíveis de doença venosa crônica (varizes, veias varicosas, edema e úlcera).

Os pacientes não se consultam espontaneamente por dor nas pernas e os médicos não consideram a dor venosa como parte da doença. Apesar do impacto da doença venosa crônica sobre os custos e a qualidade de vida, os pacientes com doença venosa crônica ainda são subdiagnosticados e subtratados.

"A progressão para estágios clínicos mais avançados devido ao tratamento tardio pode levar à perda de dias de trabalho, menor qualidade de vida e aumento dos custos globais," disse o professor Rabe, presidente da União Internacional de Flebologia.

O Programa VEIN CONSULT será executado até 2012 em mais de 20 países. Os resultados dos primeiros 70.000 pacientes avaliados de 13 países (Brasil, França, Geórgia, Hungria, México, Paquistão, Romênia, Rússia, Sérvia, Cingapura, Eslováquia, Espanha, e mirados Árabes Unidos) foram apresentados durante uma sessão inteiramente dedicada no Congresso UIP em Praga.

O Comitê Científico UIP

Notas ao editor:

Sobre a  União Internacional de Flebologia (UIP)

A União Internacional de Flebologia é uma organização internacional cujo objetivo é promover a excelência e inovação em doenças venosas e linfáticas através da educação, defesa e pesquisa.

O Programa VEIN CONSULT é realizado sob os auspícios da UIP e apoiado por uma subvenção educacional irrestrita do Servier Research Group.

Referências:

Rabe E. Atualização sobre o Programa Vein Consult: o maior programa de conscientização do mundo sobre doença venosa crônica. Resumo publicado como um suplemento sobre Flebologia Prática, reunião da sessão europeia da UIP, Praga, República Checa, 14 a 17 de setembro de 2011.

Puskas A. Primeiros resultados de 70.000 pacientes avaliados em cuidados de saúde primários no Programa Vein Consult. Resumo publicado como um suplemento sobre Flebologia Prática, reunião da sessão europeia da UIP, Praga, República Checa , 14 a 17 de setembro de 2011.

Mansilha A. Qualidade de vida e custos da doença venosa crônica: primeiros resultados do Programa Vein Consult. Resumo publicado como um suplemento sobre Flebologia Prática, reunião da sessão europeia da UIP, Praga, República Checa, 14 a 17 de setembro de 2011.

Fernandez Quesada F. Primeiros resultados dos pacientes acompanhados por especialistas no Programa Vein Consult. Resumo publicado como um suplemento sobre Flebologia Prática, reunião da sessão europeia da UIP, Praga, República Checa, 14 a 17 de setembro de 2011.

FONTE  Servier

FONTE Servier

21%

more press release views with 
Request a Demo

Modal title

Also from this source

Voranigo® (vorasidenib) de Servier recibe premios Prix Galien en varias regiones

Voranigo® (vorasidenib) de Servier recibe premios Prix Galien en varias regiones

Servier, grupo farmacéutico internacional independiente regido por una fundación, anunció hoy que Voranigo® (vorasidenib) ha sido galardonado con el...

Voranigo® (Vorasidenib) von Servier erhält Prix Galien Awards in mehreren Regionen

Voranigo® (Vorasidenib) von Servier erhält Prix Galien Awards in mehreren Regionen

Servier, ein unabhängiger internationaler Pharmakonzern, der von einer Stiftung geleitet wird, gab heute bekannt, dass Voranigo® (Vorasidenib) bei...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Clinical Trials & Medical Discoveries

Clinical Trials & Medical Discoveries

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.